About
Research
Patient Care
Education
Community
Paul Calabresi Career Development Award for Clinical Oncology (K12-Clinical Trial Optional)
PAR-22-136. Up to $750K/year (5 years). Applications due 6/15/2022, 6/15/2023, 6/17/2024. The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists trained in clinical and translational cancer research, and to promote their career development as cancer researchers. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44-Clinical Trial Optional)
RFA-CA-22-025. $4M / 3 years. LOI due 7/5/2022. Application due 8/5/2022. For previously funded SBIR/STTR Phase II only. This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.
Research Projects in Physical Sciences-Oncology (U01-Clinical Trial Optional)
PAR-22-147. $400K/year (5 years). Earliest submission-June 8, 2022. This Funding Opportunity Announcement (FOA) invites U01 cooperative agreement applications for Physical Science-Oncology Projects (PS-OP). The goal of the Physical Sciences-Oncology Network (PS-ON) is to foster the convergence of physical sciences approaches and perspectives with cancer research to advance our understanding of cancer biology and oncology by forming transdisciplinary teams of physical scientists and cancer biologists/physician scientists. Examples of physical scientists may include engineers, physicists, mathematicians, chemists, and computer scientists. The PS-OPs, individually and as a collaborative Network along with other PS-OPs and the Physical Sciences-Oncology Centers (PS-OC), will support transdisciplinary research that: (1) establishes a physical sciences perspective within the cancer research community; (2) facilitates team science and field convergence at the intersection of physical sciences and cancer research; and (3) collectively tests physical sciences-based experimental and theoretical concepts of cancer and promotes innovative solutions to address outstanding questions in cancer research.
Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01-Clinical Trial Not Allowed)
PAR-22-161. Multiple deadlines. Earliest due date: 6/29/2022. Through this funding opportunity announcement, the National Cancer Institute (NCI) solicits applications to “Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts” PAR. This funding opportunity announcement seeks to support initiating and building the next generation of population-based cancer epidemiology cohorts to address specific knowledge gaps in cancer etiology and survivorship. Specifically, it will support methodological work necessary to initiate and build cancer epidemiology cohorts that can address critical scientific gaps concerning (i) new or unique exposures in relation to cancer risks and outcomes and (ii) achievement of diverse populations in cohorts with the inclusion of understudied populations (e.g., racial/ethnic groups, rural populations, individuals living in persistent poverty areas, and others) with substantial community engagement.
NIH Director’s Pioneer Award Program (DP1-Clinical Trial Optional)
RFA-RM-22-018. $700K/year (5 years). Application due 9/9/2022. The NIH Director’s Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation’s research workforce. Thus, individuals from all backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator’s research program or elsewhere. The NIH Director’s Pioneer Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund.
Research to Understand and Address the Survivorship Needs of Individuals Living with Advanced Cancer (R01-Clinical Trial Optional)
RFA-CA-22-027. $500K/year (5 years). LOI due 8/30/2022. Application due 9/30/2022, 9/29/2023. The purpose of this Funding Opportunity Announcement (FOA) is to support studies that aim to better understand and/or address survivorship needs for individuals living with likely incurable cancer. This group is heterogenous in terms of cancer type, treatments received, prognosis, and outcomes. Specifically, this RFA is intended to solicit applications proposing 1) observational studies to understand the trajectory of physical and psychological symptoms, patterns of care, and unmet needs; and/or 2) the development and testing of interventions to improve the delivery of comprehensive survivorship care in this group of cancer survivors.
NIH Director’s New Innovator Award Program (DP2-Clinical Trial Optional)
RFA-RM-22-019. $1.5M/5 years. Application due 8/19/2022. The NIH Director’s New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds, including those from underrepresented groups and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's New Innovator Award Program complements other ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators. The NIH Director’s New Innovator Award Program is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund.
Pediatric Immunotherapy Network (PIN) (U01-Clinical Trial Optional)
RFA-CA-22-016. $450K/year (5 years). LOI due 8/27/2022. Application due 9/27/2022. Pre-application webinar on July 14, 2022 (pre-registration required). Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to solicit applications for the Pediatric Immunotherapy Network (PIN). The overall goal of this FOA is to establish a collaborative network consisting of investigators with relevant expertise to develop and advance novel translational immunotherapy approaches for children and adolescents with solid tumors including brain tumors. This FOA solicits U01 applications for discrete research projects that address relevant research opportunities focused on pediatric solid tumors (e.g., mechanisms of immune evasion, development of pre-clinical models, discovery and validation of novel therapeutic targets, development of novel pediatric immunotherapy agents and treatment approaches such as cancer vaccines, cellular therapy, and combinations with immunotherapy agents. Successful applicants will become members of the Pediatric Immunotherapy Network (PIN), which will address current challenges in pediatric cancer immunotherapy and accelerate the pace at which effective immunotherapies are realized for pediatric solid tumors.
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01-Clinical Trial Optional)
PAR-22-131. Multiple deadlines. Earliest application due 10/5/2022. This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic information and/or meta data obtained from platforms including but not limited to lower resolution diagnostic acquisitions and systemic biomarker results to high resolution single-cell analytics / imaging applied to the characterization of heterogeneous cell populations within tumor for improving current approaches for: (1) the early detection of organ confined premetastatic aggressive cancer, and, (2) identifying precancerous lesions associated with the development of a subsequent lethal phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions by improving detection sensitivity and specificity of integrated multiparametric platforms. For example, N-dimensional co-registered, cross-correlated imaging data integrated with multiplexed biomarker results and/or digital pathomics, glycomics, or metabolomic imaging using analytic strategies such as artificial intelligence or virtual reality visualization techniques. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of potentially lethal cancer versus non-lethal disease, (2) minimize/better manage overdiagnosis and (3) reduce false positives and false negatives.
FY23 Breast Cancer Research Program (BCRP)
The DoD Congressionally Directed Medical Research Programs: FY23 BCRP is currently accepting applications for Breakthrough Award Levels 1-4, Era of Hope Scholar Award, Clinical Research Extension Award, Transformative Breast Cancer Consortium Development Award, Transformative Breast Cancer Consortium Award, Innovator Award. Pre-applications (required) due March 28, 2023 or March 29, 2023.
2022 Gabrielle's Angel Foundation for Cancer Research
Blood-related cancers. Limited submission (2 junior faculty invited to apply). Requires CFCCC review and selection. $225K/3 years. Internal deadline extended to Aug 3, 2022.
Patient Resources
Below is a list of organizations dedicated to cancer research or to helping patients and their loved ones fight cancer.
Home
The UCI Chao Family Comprehensive Cancer Center (CFCCC) is the only National Cancer Institute (NCI)-designated comprehensive cancer center based in Orange County. NCI cancer centers are national leaders in cancer research, education and treatment, and centers designated as "comprehensive" are at the forefront, signifying that it has met rigorous criteria aimed at providing world-class patient care and innovative research.
NCI Research Specialist (Laboratory-based Scientist) Award (R50-Clinical Trial Not Allowed)
PAR-22-187. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These non-tenure track scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. It is anticipated that only exceptional scientists who want to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators, will be competitive for this award. Salary support and travel costs. Application due Nov 2, 2022 (LOI due 30 days prior).
NCI Research Specialist (Core-based Scientist) Award (R50 – Clinical Trial Not Allowed)
PAR-22-188. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity. Salary support and travel costs. Application due Nov 2, 2022 (LOI due 30 days prior).
2022 Steven A. Rosenberg Scholars Award (Call for Nomination)
Immune-oncology/immunotherapy. Early career. $150K. Internal deadline: July 6, 2022
FY23 Lung Cancer Research Program (LCRP)
The DoD Congressionally Directed Medical Research Programs: FY23 LCRP is currently accepting applications for the Career Development Award, Concept Award, Idea Development Award, and Translational Research Award. Pre-applications (required) earliest due May 2, 2023.
FY22 Neurofibromatosis Research Program (NFRP)
The DoD Congressionally Directed Medical Research Programs: FY22 NFRP is currently accepting applications for multiple award mechanisms. Earliest deadline: June 30, 2022.
FY23 Ovarian Cancer Research Program (OCRP)
The DoD Congressionally Directed Medical Research Programs: FY22 OCRP is currently accepting applications for Investigator-Initiated Research Award, Ovarian Cancer Academy Award-ESI, and Pilot Award. Pre-applications (required) due April 17, 2023.
FY22 Peer Reviewed Cancer Research Program (PRCRP)
The DoD Congressionally Directed Medical Research Programs: FY22 PRCRP is currently accepting applications for multiple award mechanisms. Earliest LOI due: July 12, 2022.